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Background & aims: There is limited information about the economic impact of nutritional support
despite its known clinical beneﬁts. This systematic review examined the cost and cost effectiveness of
using standard (non-disease speciﬁc) oral nutritional supplements (ONS) administered in the hospital
setting only.
Methods: A systematic literature search of multiple databases, data synthesis and analysis were un-
dertaken according to recommended procedures.
Results: Nine publications comprising four full text papers, two abstracts and three reports, one of which
contained 11 cost analyses of controlled cohort studies, were identiﬁed. Most of these were based on
retrospective analyses of randomised controlled trials designed to assess clinically relevant outcomes.
The sample sizes of patients with surgical, orthopaedic and medical problems and combinations of these
varied from 40 to 1.16 million. Of 14 cost analyses comparing ONS with no ONS (or routine care), 12
favoured the ONS group, and among those with quantitative data (12 studies) the mean cost saving was
12.2%. In a meta-analysis of ﬁve abdominal surgical studies in the UK, the mean net cost saving was £746
per patient (se £338; P ¼ 0.027). Cost savings were typically associated with signiﬁcantly improved
outcomes, demonstrated through the following meta-analyses: reduced mortality (Risk ratio 0.650,
P < 0.05; N ¼ 5 studies), reduced complications (by 35% of the total; P < 0.001, N ¼ 7 studies) and
reduced length of hospital stay (by ~2 days, P < 0.05; N ¼ 5 surgical studies) corresponding to ~13.0%
reduction in hospital stay. Two studies also found ONS to be cost effective, one by avoiding development
of pressure ulcers and releasing hospital beds, and the other by gaining quality adjusted life years.
Conclusion: This review suggests that standard ONS in the hospital setting produce a cost saving and are
cost effective. The evidence base could be further strengthened by prospective studies in which the
primary outcome measures are economic.
© 2015 The Authors. Published by Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Although there is substantial information about the beneﬁcial
effects of nutritional support on clinical outcomes, such as mor-
tality, development of conditions requiring hospital admissionsealth Research Biomedical
uthampton NHS Foundation
d, UK. Tel.: þ44 2381 20 4277.
Ltd and European Society for Clini
d/4.0/).and speed of recovery from illness [1e6], there is much less in-
formation about its economic consequences. Several systematic
reviews have been undertaken [7e11] but these have often not
separated the effects of different types of nutritional interventions
in different settings and many analyses appear to have been
missed. Furthermore, although in countries such as the UK [12]
and the Republic of Ireland [13], it has been estimated that the
cost of malnutrition exceeds 10% of the total public expenditure on
health and social care, the extent to which nutritional in-
terventions impact on the budget and produce cost-effective out-
comes is much less clear. For example, various types of nutritionalcal Nutrition and Metabolism. This is an open access article under the CC BY-NC-ND
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the same setting, have been reported to produce both a net cost
and net cost saving depending on the patient group and study
conditions [14]. At least some of the variability between studies
can be explained by the healthcare setting, the condition being
treated, and the type of nutritional support, which may vary from a
specialised form of nutritional support, such as enteral tube
feeding and parenteral nutrition, to oral nutrition support, such as
dietary advice to modify the texture or composition of the diet,
food fortiﬁcation and commercial oral nutritional supplements
(ONS). The variability in outcomes involving ONS alone also de-
pends on multiple factors, including the underlying disease,
nutritional status and both the amount and type of ONS ingested.
For example, general purpose, multi-nutrient ONS (standard ONS),
designed for the management of a wide range of patients with
disease related malnutrition contain a broad range of macronu-
trients and micronutrients in balanced proportions. These may
produce different effects than disease speciﬁc ONS for which the
macro- and/or micronutrient levels have been adapted for use in
speciﬁc clinical conditions. In the hospital setting, ONS are typi-
cally used for relatively short periods of time, often in patients
suffering from acute conditions (including the acute complications
of elective and emergency procedures) while in the community
setting, they are generally used for longer periods of time, often in
patients with chronic conditions. In view of the diverse composi-
tion of ONS, the different populations for which they are pre-
scribed, and the various clinical and economic outcomes that are
inﬂuenced by care settings and transitions between care settings,
this review focussed on addressing the following question: do
standard ONS administered only during hospitalisation produce
cost-effective outcomes and cost savings? The review also aimed
to identify gaps in knowledge that need to be addressed to help
guide clinical practice.
2. Methods
The systematic review was planned and conducted according to
published guidelines, including those provided by the Cochrane
Collaboration [15], the UK National Health Service Centre for Re-
views and Dissemination [16] (Centre for Reviews and Dissemina-
tion, 2009), and the PRISMA guidelines [17]. This review on the use
of ONS in hospital was part of a broader literature review that
included the use of ONS in the community setting which will be
reported separately [18].
2.1. Inclusion and exclusion criteria
The inclusion and exclusion criteria of the current review were
deﬁned before the literature search was undertaken. Both inter-
ventional and observational studies aiming to assess the effects of
ONS interventions on economic outcomes were eligible. Only pa-
pers or abstracts reported in English were included. Animal studies
were excluded. Studies of adults and children (>1 year of age) of
any nutritional status (malnourished and well nourished) treated
as hospital inpatients in any country were included, but studies in
pregnant and lactating women were excluded.
Studies of ONS alone or with other types of intervention, such
as dietary advice (dietary counselling) or enteral tube feeding,
were eligible for inclusion, but studies that included drug in-
terventions were excluded. For the purposes of this review, only
standard ONS were included which were deﬁned as a commer-
cially available, ready to consume, multi-nutrient (complete or
incomplete), liquid or semi-solid product providing a mixture of
macronutrients and micronutrients and produced by specialistmedical nutrition manufacturers. Studies of disease-speciﬁc for-
mulas adapted to the needs of speciﬁc diseases and/or digestive
or metabolic disorders [19] were excluded as were immune
modulating formulas. Dietary counselling was deﬁned as dietary
advice provided by a qualiﬁed healthcare worker to modify the
quantity and/or proportions of food ingested. Studies of in-
terventions with ONS, with or without other interventions, were
compared with no ONS (or routine care, which may include ONS
in a proportion of patients). Studies comparing ONS with another
type of nutritional intervention, such as dietary advice were also
eligible for inclusion. Studies that included exercise as an inter-
vention, ONS in combination with drug therapy such as anabolic
steroids, and studies of one type of ONS v. another were
excluded.
The primary outcome of this review was cost or cost
effectiveness, with no restrictions on the type of effectiveness
outcomes. The secondary outcome was any functional and/or
clinically relevant effect pertinent to cost-effectiveness analysis.
2.2. Data extraction
The literature search was undertaken on 31 March 2014. OvidSP
was used to search Embase (Embase Classic þ Embase 1947e2014
week 13) and Medline (1946e2014 March week 3). On the same
date, a literature search was carried out using the Health Economic
Evaluation Database (HEED) and the Cochrane Library (which in-
cludes the National Health Service Economic Evaluations Database
or NHS EED, Cochrane Database of Systematic Reviews, Cochrane
Central Register of Controlled Trials and Database of Abstracts of
Reviews and Effects). Articles from all of these databases were
exported into a single ‘library’. The Cost-Effectiveness Analysis
(CEA) Registry was checked independently.
The terms shown below were used to make a broad search
which included the title of publication, abstract, subject headings
and any key words. They were organised into three groups: 1.
economic, economics, cost, costs, ﬁnance, ﬁnances, budget, bud-
gets, expense, expenses, price, prices, AUD, USD, EUR, GBP, dollar,
dollars, euro, euros, pound and pounds 2. supplement, supple-
ments, ONS, sip, sips, feed, feeds, nutrition and nutritional 3. utility,
healthcare, resource, resources, effective, effectiveness, beneﬁt and
beneﬁts.
The articles were exported into a database only if they included
at least one search term within each of the three groups. Hand
searching of the references of the retrieved ﬁnal papers, and dis-
cussions with experts in the ﬁeld were also carried out. Potentially
eligible papers were identiﬁed by reading the titles, abstracts and
key descriptor words/phrases. Full papers were obtained whenever
possible according to the pre-speciﬁed inclusion criteria. The
studies were initially screened by an assessor after reading the title
and abstract, and if the publication was deemed to be potentially
relevant, the full article was reviewed. Any uncertainty about po-
tential relevance was discussed with another assessor. Relevant
abstracts were brieﬂy summarised and used to search potential full
papers by the same authors, but theywere not subjected to detailed
economic assessment as they contained insufﬁcient information.
The assessment of trial eligibility was undertaken by two inde-
pendent assessors and any disagreements were resolved through
discussion. Figure 1 shows the reasons for excluding certain
studies. Other publications were identiﬁed from prior knowledge,
contact with experts in the ﬁeld and hand searching of publications
on ONS. One of these publications was based on the National
Institute for Health and Care Excellence (NICE) costing template
[20], whichwas replicated by one author of the current review (ME)
to examine the effect of standard ONS in hospital inpatients.
Fig. 1. Flow diagram of publications included and excluded in the review.
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The assessment of the quality of studies (risk of bias) was based
on the Cochrane Handbook for Systematic Reviews of Interventions,
updated in 2011 [15] (for controlled clinical trials), Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE)
[21] (for observational studies in epidemiology), and Drummond
et al. [22] (for economic studies - applied only to prospective
studies with stated economic outcomes). In view of the lack of clear
and unambiguous economic criteria relevant to intervention
studies with ONS, a few of the items suggested by Drummond et al.
[22] were deﬁned, clariﬁed or eliminated to make them more
pertinent to the current assessment (see Supplementary File 1).
Some publications were evaluated by more than one set of criteria.2.4. Synthesis of data and statistical analyses
Comprehensive Meta-Analysis (version 2, Biostat Inc. New Jer-
sey, USA) was used to undertake random effects meta-analyses
using data that were extracted from the studies included in the
present review. When results were expressed in different units
such as different national currencies or obtained at widely different
times in different countries, the results were expressed as a pro-
portion of the total costs or of the control group. When meta-
analysis of patient level data was not possible due to lack of mea-
sures variation, the mean values from each study were analysed
(study-level analysis), using simple statistical tests such as t-tests
and the binomial test (for a cost outcome either favouring or not
favouring the ONS group), undertaken with the Statistical Package
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<0.05 (two tailed) was considered to be signiﬁcant.3. Results
A total of 22,819 publications were retrieved from the literature
search. No additional references were identiﬁed from the Cost-
Effectiveness Analysis Registry, but expert prior knowledge of the
literature identiﬁed another ﬁve publications, which were not lis-
ted and/or not retrieved from the electronic databases (3 reports
(not listed) [14,20,23], one paper [24], which was subsequently
retrievable from electronic databases, and one abstract [25]). The
original full text papers used by this review [24,26e28], and pre-
vious systematic reviews [7e11] did not use or cite the 14 economic
analyses from these ﬁve publications. Figure 1 shows that the vast
majority of studies were eliminated either because they were du-
plicates or because the titles and abstracts clearly indicated they
did not involve cost or a cost-effectiveness analysis using ONS in
hospital. After closer scrutiny of the remaining studies, including
examination of the full text for many of them, further studies were
eliminated for the reasons shown in Figure 1, leaving only nine
publications for analysis in this review [14,20,23,24,26e30]. Three
of these publications were reports [14,20,23], one of which [14]
included 11 economic analyses of controlled clinical trials
[26,27,31e39] (all of which were RCTs apart from one [27]), and
another [20] representing an update of a previous report [40]. One
of the excluded studies involved a multicomponent intervention in
which the intake of ONS in the intervention group was less than in
the control group receiving routine care [41]. Another study, with a
historical control group [42] was excluded for several reasons: only
a minority of patients in the control and intervention groups
received ONS; the control group received more ONS than the
intervention group; patients in the intervention group received
different types of oral interventions (some ONS and protein
enriched meals and others only protein enriched meals), with no
subgroup analysis. One of the 12 hospital studies in the British
Association for Parenteral and Enteral Nutrition (BAPEN) economic
report [43], was also excluded because it used a ‘home made’ feed
of unknown composition, instead of a commercial feed of known
composition. A further paper from the USA [24] did not specify
whether “complete nutritional supplement, oral” was restricted
entirely to standard ONS, but contact with one of the authors of the
paper revealed that about 80% of the ONS were standard ONS. This
paper was included in the review, but interpreted with caution.3.1. General features of studies
Supplementary File 2, Table 1 indicates the general study char-
acteristics including the funding source of individual studies and in
addition provides complementary information on the cost and
cost-effectiveness studies to that provided below. From 9 publica-
tions [14,20,23,24,26e30] fourteen cost analyses based on in-
terventions exclusively in the hospital setting were identiﬁed
(including one which was part of a cost-effectiveness analysis [28],
and one inwhich the hospital component was established from the
costing template [20]). Only three cost analyses were identiﬁed
from the literature search [26e28] and only two were prospective
[26,27]. Most analyses were identiﬁed from detailed reports pro-
duced by national organisations (NICE and BAPEN). Two cost-
effectiveness analyses [23,28] used economic models that incor-
porated data from previous publications. Most of the controlled
clinical trials used in the cost analyses included a range of clinically
relevant outcomes (mortality, muscle strength and post-operative
complications) which were reviewed.Ten cost analyses were based on data collected in the UK and
another four in USA [24], Australia [28], Belgium [37] and
Switzerland [35] (Supplementary File 2, Table 1). The two cost-
effectiveness analyses undertaken in Australia [28] and England
[23], were based on data collected in both their own countries and
other countries.
Among the eleven studies comparing ONS with no ONS, one
included the cost of nursing assistance to help with ingestion of
ONS [28], another the labour and administrative expenses [24] and
yet another the extra cost of implementing amanagement pathway
involving screening, assessment and some enteral tube feeding
[23]. Two studies compared ONS with routine care [34,36], one of
which speciﬁcally indicated that routine care included ONS (if for
example it was recommended by the dietitian) [36]. The other
study did not indicate this [34] although it was known that ONS
was used routinely in the hospital in which the study was under-
taken. Only one study compared ONS with placebo [39]. Table 1 in
Supplementary File 2 summarises the comparisons. In all studies,
ONS was given in addition to food. The study designs did not
attempt to replace food with ONS.
Calculations of ONS costs in hospital were based on the duration
and amount of the prescription, which ranged from about 5 days to
32 days and typically 300e600 kcal/day (Supplementary File 2,
Table 1). In two modelling studies, the amount of ONS used was
not stated, but the prescription and administration costs were
mentioned [24,28].
Seven studies involved malnourished subjects
[20,23,28,34,35,37,38] identiﬁedusingvarious criteria (Supplemetary
File 2, Table 1). Seven involvedmalnourished and non-malnourished
subjects according to anthropometric criteria such as BMI
[26,27,31e33,36,39], and one did not report weight or nutritional
status [24].
The main outcome measure in all four modelling studies was
either a cost [20,24] or cost-effectiveness analysis [23,28] but they
relied on information obtained from previously published studies
undertaken for other purposes. In two clinical studies, economic
data were secondary outcome measures [26,27]. These and other
clinical studies reported a variety of outcome measures, such as
weight, dietary intake, and functional and/or clinical outcome
measures.
3.2. Outcomes
3.2.1. Cost analyses: results of individual studies
3.2.1.1. Interventional studies. The two prospective controlled trials
with a cost analysis reported a net cost saving in favour of the ONS
group. In the study of Smedley et al. [26], which involved 89 pa-
tients undergoing abdominal surgery, the mean expenditure of the
ONS group was lower than that of the control group (no ONS) by a
mean of £261, with no signiﬁcant differences between groups.
Although the paper stated that the costing methodology would be
reported in a subsequent publication, this was not identiﬁed. In the
other original study which involved 181 patients undergoing or-
thopaedic surgery [27], the cost of the ONS group was also lower
than that of the control group by a median of £130.21 per patient.
The length of stay costs did not take into account the type of sur-
gery (in contrast to the analysis of the same study in the BAPEN
report). No statistical tests of signiﬁcance or measures of variation
were reported, but the paper concluded that even moderate levels
of untargeted nutritional support (prescription of 600 kcal/day)
given post-operatively can be an effective part of routine ortho-
paedic care in terms of cost and reduction in post-operative
complications.
Tables 1e3 summarise the retrospectively established mean
study level results from the BAPEN report, together with some
Table 1
Net cost saving (£ per patient) due to administration of oral nutritional supplements in individual surgical, non-surgical and mixed (surgical þ non-surgical) studies (based on
the BAPEN report 2003 prices) [14].
Studies Na Method of calculationb
Bed-days Excess Bed-days Complications
Average
(£)
Lower
quartile (£)
Upper
quartile (£)
Average (£) Average (£) Lower
quartile (£)
Upper
quartile (£)
Surgical: abdominal Beattie et al. [34] (Scotland) 101 830.6 638.5 977.7 406.7 227.0 153.3 258.7
Keele et al. [32] (England) 86 896.7 729.8 1047.2 450.2 325.6 221.5 386.5
Rana et al. [31] (England) 40 1249.4 1001.9 1478.7 612.8 596.5 387.8 752.2
MacFie et al. [33] (England) 52 1125.8 950.0 1307.6 557.6 161.6 111.2 183.2
Smedley et al. [26] (England) 89 260.7 213.3 304.8 130.1 92.9 74.0 118.6
Surgical: orthopaedic Delmi et al. [35] (Switzerland) 59 4491.2 3792.0 5280.0 2873.6 895.4 718.6 1081.5
Lawson et al. [27] (England) 181 444.9 381.0 512.6 181.0 483.3 333.7 593.8
Non-surgical Potter et al. [36] (Scotland) 381 330.4 262.4 398.4 270.4
Gazzotti et al. [37] (Belgium) 80 246.4 198.8 294.0 204.4
Gariballa et al. [38] (England) 40 2090.8 1715.3 2498.6 2527.2 116.2 95.4 130.3
Mixed: Vlaming et al. [39] (England) 281 1306.3 1046.3 1566.3 942.3
a N ¼ number of subjects in intervention (ONS) and control groups.
b Bed-day and excess bed-day costs are based on length of hospital stay. Excess bed-days are associatedwith prolonged length of stay (above the Healthcare Resource Group
Trim point), and they are usually associated with lower costs since they mostly involve basic care and hotel costs. Complication costs are based only on the costs of com-
plications. National reference costs (Health Related Groups or HRG provided by the Department of Health) to individual patients or groups of patients according to the type of
admission, type of treatment received and the type and number of complications. The authors of the primary studies were contacted to clarify uncertainties.
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studies meeting the inclusion criteria of this review showed a net
cost saving in favour of ONS. These averaged at £873/patient ac-
cording to calculations based on bed-day costs, £431/patient ac-
cording to excess bed-day costs, and £216/patient based on
complication costs. The combined abdominal and orthopaedic
surgical studies were associated with even more favourable results
(Tables 1e3). Among the three non-surgical studies, two favoured
the ONS group. When all the hospital studies in the BAPEN report
were amalgamated (surgical, non-surgical and mixed surgical and
non-surgical groups) the overall net cost saving favouring the ONS
group was either statistically signiﬁcant (calculations based on
complication costs) or close to being signiﬁcant (calculations based
on bed-day and excess bed-day costs).
In two abstracts of economic models comparing ONS with no
ONS based on previously published clinical data, the cost savingsTable 2
Summary of net cost saving (£ per patient) due to administration of oral nutritional supple
(based on the BAPEN report 2003 prices) [14].
Studies Method of calculationa
Bed-days
Average Lower quartile U
Surgical: abdominal Average 95% CI (£) 873
399, 1346
707
317, 1097
10
46
P valueb 0.007 0.007 0.
Weighted average (£)c 810.4
361.5, 1259.3
652.4
283.7, 1021.2
94
42
P valueb 0.007 0.008 0.
Surgical: abdominal þ
orthopaedic
Average 95% CI (£) 1328.5
1.4, 2658.3
1100.9
27.5, 2229.4
15

P valueb 0.050 0.054 0.
Weighted average (£)c 1062.9
108.9, 2234.7
880.0
111.5, 1871.6
12

P valueb 0.064 0.065 0.
All studies Average
95% CI (£)
924.3
63.2, 1911.9
767.2
58.0, 1592.4
10

P valueb 0.064 0.065 0.
Weighted average (£)c 332.1
526.0, 1190.3
278.9
430.7, 988.5
38

P valueb 0.409 0.402 0.
a See footnote to Table 1.
b One sample t-test where the net cost saving is tested against a value of zero.
c Sample size weighting.favoured the ONS group. In one of these, the cost saving was £138
per malnourished patient admitted to hospital [29], and in the
other £5e£460 per elderly patient at high risk of developing pres-
sure ulcers [30](the range reﬂecting the differences in ulcer stages
1e4).
3.2.1.2. Observational study. The study of Philipson et al. [24]
involved a retrospective analysis of a hospital database of 44
million adult patients admitted to hospital over an 11 year period in
the USA, fromwhich 1.16millionwere selected for the cost analysis:
0.58 million (1.6% of the total population) who received ONS and
another 0.58millionwho did not receive ONS but werematched for
age, gender and the components of the Charlson comorbidity index
(based on diagnostic groupings). The multivariate analysis, which
was undertaken to control for confounding variables including
hospital speciﬁc covariates such as the number of hospital beds andments in surgical, non-surgical andmixed (surgicalþ non-surgical) groups of studies
Excess bed-days Complications
pper quartile Average Average Lower quartile Upper quartile
23
5, 1581
431
199, 664
216
132, 564
145
83,374
267
161, 694
007 0.007 0.160 0.153 0.159
9.8
2.7, 1476.9
401.1
180.0, 622.1
205.9
82.1, 494.0
140.0
49.5, 329.5
249.4
101.1, 599.9
007 0.007 0.118 0.110 0.119
58.4
6.7, 5123.5
744.6
139.4, 1628.5
351.3
31.0, 671.6
254.0
10.1, 497.8
429.7
41.1, 818.3
051 0.085 0.036 0.044 0.035
44.7
134.9, 2624.2
578.4
196.4, 1353.2
357.9
88.3, 627.6
255.7
50.6, 460.8
435.8
108.0, 763.5
065 0.094 0.029 0.033 0.028
85.9
80.6, 2252.5
623.9
126.3, 1374.1
321.9
45.0, 598.8
234.1
24.8, 443.5
392.3
55.2, 729.4
065 0.094 0.029 0.033 0.028
5.8
630.0, 1401.6
194.8
417.9, 807.5
342.8
22.1, 707.6
245.6
30.3, 521.6
416.6
27.7, 861.0
417 0.495 0.060 0.069 0.060
Table 3
Post hoc cost analyses of hospital studies comparing ONS with no ONS or routine carea.
Study Country N Nutritional
status
Age group Type of
study
Comparison Cost saving per subject
in favour of ONS group
Cost saving
(% of control)
BAPEN report 2005 [14]
(i) Rana et al., 1992 [31] UK 40 M þ NM <65 years I ONS v no ONS £1249.4 20.71
(ii) Keele et al., 1997 [32] UK 86 M þ NM <65 years I ONS v no ONS £896.7 18.1
(iii) Smedley et al., 2004 [26],b UK 89 M þ NM <65 years I ONS v no ONS £260.7 4.93
(iv) MacFie et al., 2000 [33] UK 62 M þ NM <65 years I ONS v no ONS £1125.8 23.04
(v) Beattie et al., 2000 [34] UK 101 M <65 years I ONS v routine care £830.6 10.59
(vi) Delmi et al., 1990 [35] CH 59 M 65 years I ONS v no ONS £4491.2 39.94
(vii) Lawson et al., 2003 [27],b UK 181 M þ NM 65 years I ONS v no ONS £444.9 9.92
(viii) Potter et al., 2001 [36],b UK 381 M þ NM 65 years I ONS v routine care £330.4 10.8
(ix) Gazzotti et al., 2003 [37] BE 60 M 65 years I ONS v no ONS £246.4 7.32
(x) Gariballa et al., 1998 [38] UK 40 M 65 years I ONS v no ONS £2090.8 42.73
(xi) Vlaming et al., 2001 [39] UK 281 M 65 years I ONS v no ONS £1306.3 49.29
Banks et al., 2013 [28] AU 1356c Md 65 years I þ O ONS v no ONS V143.6 (£93.25)e
Philipson et al., 2013 [24] US 1160088 65 years O ONS v no ONS $4734 (£3148)e 21.6
NICE 2012 [20] UK 1410440c M I þ O ONS v no ONS f
UK ¼ United Kingdom; CH ¼ Switzerland; BE ¼ Belgium; AU ¼ Australia; US ¼ United States; M ¼ malnourished; NM ¼ non-malnourished; I ¼ interventional study;
O ¼ observational study.
a Calculations of costs were based on bed-day costs.
b The data in the BAPEN report were used in preference to those reported in the original papers for consistency in calculations based on bed-day costs. In the BAPEN report
the costs of speciﬁc surgical procedures were taken into account in estimating bed-day costs but the original papers the calculations did not involve the surgical procedure. For
example, in the original paper by Smedley et al. [26] a cost saving of £271 per patient translates to 11.91% of the cost of the no ONS group, while in the BAPEN report a cost
saving of £292 per patient translates to only 4.93% of the cost of the no ONS group.
c These ﬁgures which are incorporated into economicmodels are not based on clinical studies. In the study of Banks et al. [28] the number represents the point prevalence of
malnourished subjects in relevant hospitals in Queensland and in NICE 2012 [20] the number of relevant hospital admissions in one year. For the NICE model, see alsof.
d Considered to be malnourished by Banks et al., although some of the patients in a meta-analysis that was used in the model were not by anthropometric criteria.
e Based on the average currency exchange rate for the years in which the costs were calculated by the studies. The cost per patient was calculated using data provided in the
paper.
f Although there is clear net cost saving associated with the use of ONS, the exact amount depends on calculation procedures, which in turn depend on the proportion of
patients assessed by a dietitian and the proportion given ONS by the dietitian and independently of the dietitian (calculations undertaken by one of the authors (ME) using the
NICE costing template).
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status. Instrumental variables analysis was undertaken to mitigate
against potential selection bias associated with unknown variables.
The reported length of hospital stay was 21.0% shorter in the ONS
group (8.59 v. 10.88 days), which together with a consideration of
other variables resulted in a net cost saving of $4734 (se $10.07) per
episode in favour of the ONS group (21.6% cost saving). The authors
of the paper felt that the results of instrumental variables analysis,
supported by some validity tests, formed an appropriate basis to
adjust for unknown confounding variables. For example they
considered the possibility that ONS use (the instrument) might be
related to provider ‘quality’ (a ‘valid’ instrument would be expected
to show no correlation). Therefore, the authors correlated ONS use
and ‘hospital quality’ as measured by the adoption of 11 new
technologies such as cardiac catheterisation, thrombolysis and
image guided surgery. They reported no signiﬁcant relationships or
inconsistent relationships, some of which were positively related
and others negatively related. They also found that when
comparing high and low ONS propensity hospitals, there were only
small differences in co-morbidities, such as cardiovascular disease,
although these were often signiﬁcant due to large sample sizes.3.2.1.3. Studies with interventional and observational components.
Themodel used by Banks et al. [28] predicted a total annual net cost
saving of V2,869,526 (sd V2,078,715) in Queensland, Australia,
when appropriate nutritional support was used to prevent devel-
opment of pressure ulcers.
The 2012 NICE costing report also concluded that there was an
overall net cost saving in favour of the proposed pathway (£71,800
per 100,000 general population of England [20]). The model, which
was based on an earlier one that also found a net cost saving in
favour of the proposed pathway [40], was dominated by the effect
of ONS in reducing length of hospital stay (the percentagereduction in costs was not reported and could not be computed
from the costing template). This was more than sufﬁcient to
counteract the extra costs of screening, assessment and treatment
with ONS, ultimately producing a net cost saving.
3.2.2. Cost analyses: results of amalgamated studies
3.2.2.1. Subject level analyses (based on meta-analyses of studies
comparing mean ± sd between groups). Figure 2 shows the meta-
analysis of the net cost saving of ﬁve UK studies, all involving
abdominal gastrointestinal surgery and all based on 2003 prices.
The overall summary statistic favoured the ONS group (cost saving
£746/patient (se £338), P ¼ 0.027; I2 ¼ 0%) (upper graph). The
percentage cost saving (13.2% (se 6.0%), P ¼ 0.027; I2 ¼ 0%) also
signiﬁcantly favoured the ONS group (lower graph).
3.2.2.2. Study level analysis (based only on the difference in mean
values between groups). Twelve studies were found to produce a
net cost saving favouring the ONS group by amean 12.2% (sd 23.8%)
(P ¼ 0.105 using the one sample t-test for the difference between
groups, and P ¼ 0.050 using the one sample Wilcoxon signed-rank
test (the results tended to be skewed; Kolgomorov Smirnov test;
P ¼ 0.135)). Out of 14 studies for which it was possible to dichot-
omise the results into those favouring and not favouring the ONS
group, 12 favoured the ONS group (P ¼ 0.013; the binomial test).
The results in Table 4 show the summary results of subgroup
analysis according to mean age of the study populations (<65 years
v. 65 years), nutritional status (malnourished v. combination of
malnourished and non-malnourished subjects), type of interven-
tion (ONS v. no ONS and ONS v. routine care), and type of analysis
(prospective v. retrospective; interventional v. observational). They
universally favoured the ONS group, but the number of studies was
small and the variation between them was large, with the result
that the net cost saving was often not statistically signiﬁcant.
Fig. 2. Meta-analysis (with inverse variance weighting) of net cost saving of ﬁve randomised controlled trials of abdominal surgery in the UK (N ¼ 358) Upper graph results are
presented in GBP (£) (2003 prices) (mean cost saving £746/patient (se £338), P ¼ 0.027; I2 ¼ 0%) Lower graph results presented as percent reduction of control group (mean cost
saving 13.2% (se 6.0%), P ¼ 0.027; I2 ¼ 0%). Negative signs indicate cost saving * based on retrospective data analysis as provided in the BAPEN report [14].
Table 4
Cost saving (study level analysis) in favour of the ONS group by age, nutritional status and study designa,b.
% cost-saving (continuous data) Cost saving (binary data)
N studies Mean and SD P valuec N studies favouring ONS/total N P valued
<65 years 5e 15.5 ± 7.5 0.010 5/5f 0.063
65 years 7g 9.8 ± 31.4 0.442 6/8h 0.310
Malnourished 5i 7.3 ± 37.9 0.688 5/7j 0.219
Malnourished þ non malnourished 6k 14.6 ± 7.1 0.004 6/6l 0.125
ONS v no ONS 10m 12.4 ± 26.3 0.169 10/12n 0.039
ONS v routine care 2o 10.7 ± 0.149 0.006 2/2p 0.500
Interventional studies 11q 11.3 ± 24.8 0.162 9/11r 0.065
Observational ± interventional studies 1s 21.6 3/3t 0.250
a Based on data presented in Table 3.
b None of the comparisons between subgroup categories was signiﬁcant (Student's t-test for continuous data and Fisher's Exact test for binary (dichotomous) data).
c One sample t-test (against a test value of zero).
d Binomial test (against test proportion of 0.5 (favouring or not favouring ONS group)).
e Refs. [26,31e34].
f Refs. [26,31e34].
g Refs. [24,27,35e39].
h Refs. [24,27,28,35e39].
i Refs. [34,35,37,38].
j Refs. [28,34,35,37e40].
k Refs. [26,27,31e33,36].
l Refs. [26,27,31e33,36].
m Refs. [24,26,27,31e33,35,37e39].
n Refs. [24,26e28,31e33,35,37e40].
o Refs. [34,36].
p Refs. [34,36].
q Refs. [26,27,31e39].
r Refs. [26,27,31e39].
s Ref. [24].
t Refs. [24,28,40].
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related to the year of publication of the study (r ¼ 0.298, P ¼ 0.348;
N ¼ 12 studies) or to the estimated average (mean or median)
duration of ONS administration (r ¼ 0.186, P ¼ 0.563; N ¼ 12
studies).3.2.3. Cost-effectiveness analyses: results of individual studies
The probabilistic cost-effectiveness model of Banks et al. [28]
suggested that use of nutritional support (mainly ONS; compared
to no speciﬁc additional nutritional support) in elderly patients in
hospitals in Queensland, Australia, avoids development of 2896 (sd
632) cases of pressure ulcers per year, whilst releasing 12,396 (sd
4991) bed days, and producing savings of V2,869,526 (sd
V2,078,715) per year. It was not possible to accurately assess the
stage of pressure ulcers, which would have inﬂuenced the costs.
This study used information from a previously published meta-
analysis of ﬁve RCTs [44], which showed that nutritional support
prevented the development of pressure ulcers (odds ratio 0.74) in a
high risk group of patients. When the data was re-analysed by one
of the authors of the meta-analysis who is also an author of the
present review (ME), the summary result was virtually unaffected
when the single tube feeding study was excluded from the meta-
analysis (odds ratio 0.75) or when the single study with disease
speciﬁc ONS was excluded (odds ratio 0.73).
In the report commissioned by NICE [40], the incremental cost
per QALY gained was £6,608, which was considered to be cost
effective using the threshold of £20,000 per QALY gained. A large
number of one-way sensitivity analyses conﬁrmed the cost
effectiveness when the new pathway incorporating the NICE
guidelines on nutritional care was compared to the current
pathway of care. A possible exception concerned a scenario where
the reduction in mortality attributable to ONS was small (or the
relative risk high; the meta-analysis from the systematic review
showed the relative risk to be 0.84 (95% CI 0.68, 1.03)) and the
duration of intervention long and without increased health gains. A
two-way sensitivity analysis showed that both an increase in
prevalence of malnutrition and mortality ampliﬁed the cost
effectiveness. With a prevalence of malnutrition of >8% and a
mortality of about 4%, which was considered to apply to the inpa-
tient population, the incremental cost-effectiveness ratio was
<£6000 per QALY gained. Furthermore, if enteral tube feeding was
excluded from the model to restrict the nutritional support to ONS,
even the new pathway would be expected to become more cost
effective, albeit to a small extent given that in the model, enteralFig. 3. Random effects meta-analysis of mortality reported in hospital studies with econom
studies that reported mortality at 3 months and 6 months are indicated according to origintube feeding contributed little to the overall costs and apparently
not at all to the additional QALYs gained. The report also indicated
that the proposed pathway involving screening, using the ‘Malnu-
trition Universal Screening Tool’ (‘MUST’) and use of ONS was also
cost effective compared to one involving clinical screening by
nurses followed by ONS (base case analysis for incremental cost-
effectiveness ratio was £4339 per QALY gained).
Other studies without quantitative relationships between costs
and effectiveness (outcome) measures have been considered in the
cost-analysis section above. Reviewed studies reporting clinically
relevant effectiveness measures are summarised below.
3.2.4. Cost-effectiveness analyses: a consideration of clinically
relevant outcomes from individual and amalgamated studies
3.2.4.1. Mortality. There were no deaths in most studies involving
elective surgical admissions, although in one of them there were
three deaths out of a sample of 53 patients [33], and in another, two
deaths before study day one, out of a sample of 100 subjects [32].
Mortality was greater among patients admitted acutely, who were
also generally older [35,36,38]. In a study with a factorial design, no
mortality statistics were reported in the subgroup analysis of ONS
alone v. placebo alone [39], although in the study as a whole there
were 12 deaths out of 275 in the group that had ONS with or
without additional vitamins and 14 deaths out of 274 in the group
that received placebo with or without vitamins. In another study
[37], the two deaths in each group were reported at the end of the
investigation period which involved two months supplementation
in the community. Further analyses were restricted to studies in
which the effects of ONS administration in the hospital setting
alone could be evaluated. A meta-analysis of studies reporting at
least one death [32,33,35,36,38,39] (studies with no deaths are
ignored by meta-analyses of mortality), including the one in which
deaths occurred before study day one [32] and two others with
mortality statistics at three months [36] or six months [35] after
admission, found fewer deaths in the group that received ONS in
hospital (risk ratio, 0.691 (95% CI, 0.483, 089); P ¼ 0.043; I2 ¼ 0%;
N ¼ 6 studies). Without the study of Vlaming et al. [39], which
included vitamin supplementation in some of the subjects, the
summary statistics changed little (risk ratio 0.650 (95% CI, 0.432,
0.976); P ¼ 0.038; I2 ¼ 0%; N ¼ 5 studies) (Fig. 3).
3.2.4.2. Complications. Out of the seven surgical studies with cost
analyses (all favouring the ONS group), six reported complication
rates. Four of these [27,31,32,35] found signiﬁcant differencesic outcomes (Risk ratio 0.650 (95% CI 0.432, 0.976), P ¼ 0.038; I2 ¼ 0%, P ¼ 0.459). The
ally designated group.
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them included mortality among the complications [35]). A meta-
analysis (random effects model) of complications in the ONS
group (after adjustment for sample size differences between the
ONS and control groups) found that the proportion of total com-
plications was 35.3% (se 7.6%) less in the ONS than control group;
I2 ¼ 23.9% (Fig. 4).
3.2.4.3. Length of hospital stay. The mean length of hospital stay in
all surgical studies favoured the ONS group [26,27,31e35] but one
of the ﬁve UK studies did not report measures of variability be-
tween subjects [33]. Therefore, the meta-analysis of the ﬁve UK
studies was subjected to a sensitivity analysis in which the highest
and lowest standard deviations obtained from other UK studies
were assigned to this study. Both meta-analyses favoured the ONS
group by 2.0 days (P ¼ 0.038) and 2.2 days (P ¼ 0.009) respectively
(corresponding to 13.0% (P¼ 0.038) and 13.9% (P¼ 0.010) reduction
in hospital stay respective). Among the other six hospital studies for
which cost analyses were available, four reported median length of
stay. Overall, 10 out of the 12 studies had a mean or median length
of stay that was shorter in the ONS group (P¼ 0.039, binomial test).
3.2.4.4. Other outcomes. Two studies reported fatigue scores, one
in which there was no signiﬁcant change in the ONS group and a
signiﬁcant deterioration in the no ONS group [32], and the other in
which there was no signiﬁcant difference between groups [26].
Among four studies that measured grip strength, one reported
signiﬁcantly higher strength in the ONS than the control (no ONS)
group at the time of discharge [31], another a signiﬁcant deterio-
ration only in the control group at the time of discharge [32], and a
further two studies no signiﬁcant difference between groups dur-
ing hospital stay [27,34]. One study of elective hospital admissions
measured well-being [32] and another psychological status [33],
with no signiﬁcant differences between groups. Of three studies
involving emergency admissions, two reported no signiﬁcant dif-
ferences between groups in discharge destination [36,37] and the
other did not report discharge destination (or functional outcomes)
[39].
Some studies reported signiﬁcantly less weight loss in the ONS
than the control group [32,34], others reported a signiﬁcant weight
loss in the no ONS (or routine care group) but not in the ONS group,
and yet others reported no signiﬁcant differences between groupsFig. 4. Random effects meta-analysis of complications in surgical patients expressed as perc
group (difference 35.3 (se 7.6)%, P < 0.001; I2 ¼ 23.9%, P ¼ 0.247).[27,33,36e38]. Two studies did not report changes in weight
[35,39] and in one, the weight changes were reported only after
discharge from hospital when ONS was still being used [37].
4. Assessment of risk of bias
The overall quality of the studies with respect to the combined
clinical and economic outcomes, were judged to have at least a
moderate risk of bias, with substantial variation between studies
(for details see Supplementary File 1).
5. Discussion
This review, mainly of RCTs in which national reference costs
were assigned to speciﬁc conditions and interventions, suggest that
the use of ONS compared to ‘no ONS’ or routine care can produce
signiﬁcant net cost savings. Study level analyses showed a signiﬁ-
cant overall cost saving, and a series of subgroup analyses according
to malnutrition, age group, type of study and study design (Table 3)
universally favoured the ONS group, although only some of these
cost savings were signiﬁcant. The cost savings were generally found
to be associated with a range of favourable clinical outcomes, such
as reduced complications (less suffering), reduced mortality (more
QALY), and reduced length of hospital stay (earlier return to the
familiar home environment). These ﬁndings are consistent with
other reviews on the use of ONS in clinical practice [3,4,6]. Eco-
nomic models involving interventions with ONS e.g. that used by
Banks et al. [28] showing a cost-effective reduction in the risk of
developing pressure ulcers (consistent with data reported previ-
ously [30]), and the NICE model showing cost-effective improve-
ment in QALYs gained, made some assumptions (see Methods), but
their conclusions were strengthened by the use of a probabilistic
model [28] or a series of sensitivity analyses respectively [40].
The favourable cost and cost-effectiveness outcomes associated
with the use of ONS in the hospital setting could have been pre-
dicted, partly because other studies have suggested that ONS have a
range of favourable clinical effects [3,4,6], and partly because the
cost of ONS is small compared to total hospital costs., However, it is
probably more insightful and more useful for health planning and
policy making to consider these issues using a single management
model that extends between settings, rather than separately within
an individual care setting. For example, in the NICE cost-entage of total complications. A negative sign indicates fewer complications in the ONS
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alive, which required additional costs to care for their extended
lifespan outside hospital. Conversely, use of ONS in the community
can reduce hospitalisation [45]. Furthermore, ONS prices can differ
between care settings, which means there is a need to consider the
whole health and social care economy rather than one setting in
isolation.
The notable lack of primary cost analyses in adults and the total
absence of identiﬁable studies in children from the literature search
weaken the generalizability of the ﬁndings, although one retro-
spective analysis based on observational data in children has been
published since our literature search [46], which suggests that ONS
reduces length of hospital stay by 14.8% and costs by 9.7%.
Our review included only two controlled trials that prospec-
tively reported a cost analysis [26,27], and in neither of them was
cost or cost effectiveness the primary outcome variable. The only
observational study reporting a retrospective cost analysis exclu-
sively in the hospital setting found a highly signiﬁcant cost saving
favouring the ONS group (21.6% or $3694 per episode) [24], but
since disease-speciﬁc feeds were used in about a ﬁfth of patients,
care should be exercised in attributing all the reported beneﬁts to
standard ONS. Extrapolation of the ﬁndings to the entire population
of malnourished people admitted to hospital should also be made
with caution since ONSwere given to only 1.6% of patients admitted
to hospital (the prevalence of malnutrition is expected to be more
than an order of magnitude higher), whose nutritional status was
not reported. This study aimed to control for both known and un-
known variables from the observational data using instrumental
variables analysis, but despite ‘validity checks’, it is not possible to
deﬁnitively prove that bias due to unknown variables has been
totally eliminated. Some analysts have suggested that in some cir-
cumstances misleading results may be produced by instrumental
variables analysis [47e49]. There is generally less concern about
this type of bias with RCTs because the randomisation aims to
distribute both known and unknown variables equally between the
study groups. However, whilst RCTs have greater internal validity,
they have less external validity than observational studies (more
representative and larger samples, e.g. 1.16 million in the study by
Philipson et al.) [24]. Both types of studies have merits and help to
build a more complete picture.
The majority of studies compared ONS with no ONS under
controlled conditions, which means that the results may not be
directly extrapolated to routine practice where ONS is already given
to a proportion of patients under less well controlled conditions.
Nevertheless, there is a need for routine nutritional screening and
increased awareness about the importance of nutrition in clinical
practice to help reduce the burden of untreated malnutrition.
It is clear from this review that much primary research needs to
be undertaken to establish a more robust quantitative evidence
base from studies primarily designed to examine the cost and cost
effectiveness of standard ONS in various groups of patients. This is
because the quality of the reviewed studies was judged to be var-
iable with at least a moderate overall risk of potential bias. Most of
the studies were not primarily designed to assess economic out-
comes, most were analysed retrospectively, and the results of the
modelling studies that aimed to assess cost or cost effectiveness as
the primary outcome variable relied on data obtained by studies
designed to assess non-economic outcomes. Most of the reviewed
studies were funded by industry (Supplementary File 2, Table 1)
raising the potential risk of publication bias, i.e. the selective
reporting of studies with favourable outcomes. However, potential
publication bias also exists with government funded projects [50].
Recently a call has been made to register and publish the results of
all trials, to improve on the 40e50% publication rate observed be-
tween 1999 and 2007, which applies equally to industry andgovernment funded trials [50]. Although this review has focussed
on standard ONS produced commercially, which are reimbursed to
a variable extent acrossmarkets, there is also a need to review other
forms of nutritional support, such as snacks, food fortiﬁcation, di-
etary advice (for which the clinical and economic evidence base
appears to be weak) and tube feeding, and to examine their relative
cost and cost effectiveness. The cost and cost effectiveness of
disease-speciﬁc ONS requires a separate review.
Given the variable nutritional status of patients included in
different clinical trials and the use of different screening in-
struments used to identify risk of malnutrition, it would be valuable
to establish the relative beneﬁts of the use of ONS in patients with a
low body mass index, those with unintentional weight loss (which
may occur in underweight as well as overweight or obese in-
dividuals), and those with major reductions in recent nutritional
intake during key phases of their illness.
Despite variations in study design and quality (risk of bias), this
comprehensive systematic review found that use of ONS consis-
tently produced cost savings and cost-effective outcomes. The
extent to which this can be translated into routine clinical practice
depends on the degree to which a healthcare system is competent
to take advantage of these ﬁndings. Such competency varies be-
tween healthcare systems, which prioritise nutritional support to a
variable extent, and which operate different incentivisation
schemes, including those that reward high quality practice and/or
penalise poor practice. Furthermore, since many of the results of
this review were dominated by studies undertaken in the UK over
more than two decades, some caution should be taken in extrap-
olating them to a wide range of other countries using different
healthcare systems and national tariffs.
Finally, this work highlights two important methodological is-
sues. First only a minority of the economic analyses were identiﬁed
from the search engines, the majority being pinpointed by spe-
cialists in clinical nutrition (see Results section) who identiﬁed
relevant information in detailed reports produced by national or-
ganisations. When an evidence base is gathered by people who are
familiar with systematic review methodology but not the speciﬁc
topic of the review, there is a risk that important information will
be missed. Second, the criteria for assessing the quality of RCTs are
not necessarily the best ones for assessing economic studies and
vice versa, which is why in this review both types of assessments
were done. Furthermore, since publishedmethods for assessing the
quality of economic evaluations have not been speciﬁcally devel-
oped for nutrition studies, the checklist by Drummond et al. was
carefully considered and certain items deﬁned in order to make
them more relevant and speciﬁc to nutrition studies under
consideration.
6. Conclusion
This review suggests that use of standard ONS in the hospital
setting generally produce cost savings and are cost effective in
patient groups with variable age, nutritional status and underlying
conditions. More high quality prospective studies with adequate
power to examine economic outcomes are needed to substantiate
the ﬁndings of this review in countries with different healthcare
economies.
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